Veloxis CEO Polvino: How 'Orphan' Tacrolimus Will Beat Astellas Transplant Franchise
This article was originally published in Scrip
Executive Summary
Veloxis Pharmaceuticals A/S has received orphan drug designation from the US FDA for its recently approved extended release tacrolimus product Envarsus XR, a rare achievement for a product which contains a previously approved active ingredient. CEO William Polvino explains to Scrip why the tacrolimus-based Envarsus XR secured orphan drug status, and how it plans to compete with Astellas and its established tacrolimus franchise.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.